Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lankenau Medical Center, Pennsylvania Clinical Trials

A listing of Lankenau Medical Center, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (126) clinical trials

Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study

Technical Success: Alive, with Successful access, delivery and retrieval of the device delivery system, and Deployment and correct positioning (including repositioning/recapture if needed) of the single intended device, and No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure Device Success: Alive and ...

Phase

1.09 miles

Learn More »

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This multicenter study will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents. Two combinations are being studied: the first combination study will combine niraparib with the anti-programmed cell death protein (PD)-1 monoclonal antibody, JNJ-63723283 in participants with metastatic castration-resistant prostate cancer (mCRPC). The second combination will ...

Phase

2.19 miles

Learn More »

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Up to 7 sites in the US only with approximately 18 patients for Phase 1b portion (3 patients per dose group) of the study. Additional patients may be enrolled into the Phase 1b portion of the study depending on the safety and tolerability assessment in the dose escalation scheme. Approximately ...

Phase

2.19 miles

Learn More »

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

The study is a multi-center, parallel, randomized, double-blinded study with subsequent follow-up period of two years. Eight-four subjects across twelve sites will be randomized 1:1 to receive either a corneal tissue that have been cross-linked or not cross-linked (No UVA light source). Cross-linking is a term that refers to the ...

Phase

2.66 miles

Learn More »

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

MCL is a rare subtype of non-Hodgkin lymphoma that is considered incurable with conventional therapy. For relapsed patients, Ibrutinib, lenalidomide, and bortezomib are all approved by the FDA but are not curative. Novel approaches are required to improve outcomes for patients with relapsed/refractory MCL. This is an open-label study that ...

Phase

3.73 miles

Learn More »

Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer

The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.

Phase

3.73 miles

Learn More »

A Study to Assess the Safety Tolerability and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Once consented, study participants will progress through the following stages: Screening: in-person visit at the study site to confirm eligibility for proceeding Collection: autologous (self) blood stem cells are harvested at the study site, also known as apheresis Manufacturing of ST-400: no study participant activities expected Infusion: conditioning chemotherapy, followed ...

Phase

3.73 miles

Learn More »

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

Open-labelled pilot clinical trial of Zepatier (Grazoprevir + Elbasvir), Epclusa (Sofosbuvir + Velpatasvir), or another appropriate DAA in at least 10 HCV-negative subjects receiving a lung transplant from a hepatitis C (HCV)-positive donor. Eligible subjects will receive a lung transplant from a deceased-donor, and then will receive treatment after lung ...

Phase

3.73 miles

Learn More »

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Study duration per participant is approximately 112 weeks including: an approximately 56-day screening/baseline period, an approximately 52-week study observation period including 1 treatment day, and an approximately 52-week safety follow-up period. The end of study visit will be approximately 104 weeks after the Investigational Medicinal Product (IMP) administration. After completion ...

Phase

3.73 miles

Learn More »

RGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome)

MPS II is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase (IDS) gene . Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE) is the only approved product for the treatment of Hunter syndrome, however, ERT as currently administered does not cross the Blood Brain Barrier and ...

Phase

3.73 miles

Learn More »